HomeTest MenuSTI Panel — Men
Male STI Screening · 8-Target Multiplex

One Specimen. One Report. Done This Week.

Eight male-specific targets from a single urethral swab or first-void urine — chlamydia, gonorrhea, trich, Mgen, HSV-1/2, syphilis, and chancroid — reported per-target in 24–48 hours.

The Men's STI Bench
0
Male-Specific Targets
0
Specimen Workflow
0
Hour TAT for results
0%
Per-Target Reporting
The clinical problem
Symptomatic men deserve a one-tube answer.

Sending separate orders for chlamydia, gonorrhea, Mgen, and HSV is a relic. The patient with dysuria and discharge in front of you needs one specimen and one report, with each target read independently.

Eight targets, one draw, 24–48 hours — engineered for urgent care, urology, and primary care practices that want to close the loop before the patient walks out.

By the Numbers

The clinical weight behind this panel.

Industry statistics from public-health bodies and peer-reviewed literature — context for why this testing matters.

1.6M+
U.S. chlamydia cases reported in 2022

Reported rates underestimate true prevalence in men.

Source · CDC
~50%
of urethral gonorrhea in men is asymptomatic or mildly symptomatic
Source · CDC
Resistant
N. gonorrhoeae now resists nearly every prior first-line antibiotic

Confirmatory NAAT + resistance awareness is non-negotiable.

Source · CDC AR Threats
≥3 sites
recommended sampling (urethral, rectal, pharyngeal) for MSM
Source · USPSTF / CDC

Figures reflect publicly reported epidemiology and clinical literature for context only. They are not performance claims for the Chaseville Labs assay. See individual citations from the U.S. Centers for Disease Control and Prevention, World Health Organization, National Institutes of Health, and peer-reviewed journals.

What This Panel Diagnoses

Conditions, syndromes & infections covered.

The clinical scenarios where this panel is the right call — built around the differential your providers are actually working through.

Bacterial STIs

3
Chlamydia (Chlamydia trachomatis)

Leading cause of non-gonococcal urethritis (NGU); often asymptomatic but transmissible.

Clinical Impact ·Drives same-week treatment, partner notification, and reportable disease follow-up.
Gonorrhea (Neisseria gonorrhoeae)

Urethritis, proctitis, and pharyngitis — drug-resistant strains are rising globally.

Clinical Impact ·Confirmation triggers CDC-aligned dual therapy (ceftriaxone + doxycycline).
Mycoplasma genitalium (Mgen)

Persistent or recurrent urethritis after standard therapy — frequently the culprit when CT/NG are negative.

Clinical Impact ·Detection prompts macrolide-resistance testing; moxifloxacin may be needed.

Other Genitourinary Infections

2
Trichomoniasis (Trichomonas vaginalis)

Often asymptomatic in men but transmissible — frequently the source of female partner recurrence.

Clinical Impact ·Treats both partners in one visit; molecular catches what microscopy misses.
HSV-1 / HSV-2 — Genital Herpes

Type-specific identification of genital ulcer disease.

Clinical Impact ·Guides suppressive antiviral therapy and informs partner transmission counseling.
Complete Target List

8 targets, resolved from a single specimen.

Each organism below is reported individually as Detected, Not Detected, or Inconclusive — grouped here by pathogen class for clinical scanability.

Targets

6 targets
Chlamydia trachomatisNeisseria gonorrhoeaeTrichomonas vaginalisMycoplasma genitaliumHSV-1HSV-2
Why Molecular

Culture was built for a different century.

Multiplex real-time PCR resolves what culture and rapid antigen miss — fastidious organisms, polymicrobial infections, viruses, and resistance markers — from a single specimen.

Conventional
The Old Way

Culture & rapid antigen

  • 3–5 days
    Patient empirically treated before any answer arrives
  • Misses fastidious & viral organisms
    No growth ≠ no infection
  • Single-organism bias
    Polymicrobial infections under-reported
  • No resistance data
    Susceptibilities arrive a day later, if at all
  • Specimen-quality dependent
    Pre-treated patients culture negative
Multiplex PCR
The CRL Way

STI Panel — Men on Bio-Rad CFX384

  • 24–48 hours
    Most reports back the next clinical day
  • 8 targets, one run
    Bacterial, viral, fungal, and parasitic in a single multiplex
  • Detects what culture can't
    Fastidious organisms, viruses, and polymicrobial infections, all reported individually
  • Validated LDT
    CLIA-certified, internally controlled, per-target Detected / Not Detected reporting
Primary Specimen
Urine, urethral swab
Collection Container
Sterile collection device per specimen type
Volume
Per collection protocol
Storage
2–8°C up to 72 hours
Transport
Pre-paid FedEx Priority Overnight
Stability
Validated per storage condition
Chain of Custody
Barcoded, temperature-logged in transit
Result Format

Per-target results, with clinical context.

Every analyte is reported individually as Detected, Not Detected, or Inconclusive. What a Detected result means clinically depends on which category the target falls into:

Targets
Chlamydia trachomatisNeisseria gonorrhoeaeTrichomonas vaginalisMycoplasma genitaliumHSV-1HSV-2
If Detected

Detected pathogens confirm the etiology of urethritis or proctitis and direct CDC-aligned treatment. Mycoplasma genitalium detection should prompt consideration of macrolide-resistance testing; HSV-1/2 typing supports recurrence and transmission counseling.

Qualitative multiplex real-time PCR (Bio-Rad CFX384)
Turnaround: 24–48 hours